About Exacta
Every human being is different and unique, similarly every person’s cancer also is unique. However, conventional ‘Standard of Care’ approach does not take into consideration the overall genetic architecture of a particular patient‘s tumour and consequently, patients could suffer due to failed therapies or aggressive relapse.
It is, thus, imperative that the genetic architecture of the tumour is studied comprehensively before deciding the treatment plan, which has to be personalised to individual patients and their disease.
It is a risk-assessment tool that can provide independent and improved prognostic value when compared to the usual tumour risk parameters and is intended to be used as an adjunct to the standard TNM classication system, in order to assist in guiding a patient’s management.
Why Exacta?
exacta® is a comprehensive in depth tumour gene expression analysis. It analyses 100’s of millions of data points at the molecular level to reveal all possible targets for precision drugs.
exacta® helps unravel the driver mutations and pathways that are propelling a particular person’s cancer through multi-analyte and multi-coordinate analysis over 20.805 genes in the cancer genome. This analysis helps identify targeted drugs that would be most effective for a particular cancer. exacta®, thus enables a highly sophisticated treatment strategy beyond conventional perspective, even for difficult cancers.
When to use Exacta?
exacta® is particularly recommended for cancer patients where ...
What will your Exacta results tell you?
exacta® Analysis Unravels Most Optimal Targeted Therapy Selection:
exacta® molecular analysis for possible molecular targets and cell cycle pathways to identify the most appropriate molecular targets for targeted therapy. All relevant biomarkers for targeted therapy selection, including mutations, deletions, gene rearrangement, gene amplification / expression, are analysed. Confounding impact of simultaneous resistant molecular alterations on sensitising mutations giving better therapy selection than single gene test based therapy.
Most Optimal Cytotoxic Therapy Selection:
Cytotoxic drug response / resistance of cancer genome, based on DNA and gene expression. Comprehensive exacta® includes chemo-sensitivity testing for cytotoxic drug efficacy prediction.
Drug Toxicity / Adverse Drug Reactions:
Selection of therapy with minimal side effects and best tolerance based on germline drug metabolising enzyme (DME) response for likely drug toxicity/ADR prediction.
Drug Repurposing:
With recurrent or high grade cancer which has progressed despite therapy. exacta® can explore all possible therapeutic options by analysing all molecular alterations.
Longitudinal Disease / Therapy Monitoring:
Comprehensive exacta® enables effective tumour burden monitoring, therapy response monitoring and helps detect early therapy failure or recurrence.
Therapy Recommendation (TR):
Proprietary exacta® analysis provides best therapy combination option to treating physician.
How long will the results take?
exacta® results are released to the requesting Oncologist within 10 days, after the specimen has been received by the Datar Cancer Genetics laboratory.
Please note: the time it takes for the local pathology laboratory to release the sample and transit time to the lab may vary and is not included in the turn around time mentioned above.
Would you like more information?
To find out more, please call us on +61 1300 282 482 or fill out an enquiry form here.